GBT - Global Blood Therapeutics Stock Price, News & Analysis

$38.35 0.05 (0.13 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$38.30
Today's Range$37.72 - $39.00
52-Week Range$13.35 - $43.95
Volume693,864 shs
Average Volume999,502 shs
Market Capitalization$1.68 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Global Blood Therapeutics (NASDAQ:GBT)

Global Blood Therapeutics logoGlobal Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD). The Company is evaluating GBT440 in SCD in a Phase III clinical trial of GBT440 in adult and adolescent patients with SCD. GBT440 inhibits abnormal hemoglobin polymerization, the underlying mechanism of RBC sickling. The Company is also engaged in other research and development activities targeted towards hereditary angioedema (HAE). The Company's GBT440 is an investigational drug that increases hemoglobin's affinity for oxygen by binding to the alpha-chain of hemoglobin. GBT440 has been observed to keep a proportion of sickle hemoglobin (HbS), in its oxygenated state, where it cannot participate in polymerization.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: N/A
  • Sector: Healthcare
  • Symbol: NASDAQ:GBT
  • CUSIP: N/A
  • Web: www.globalbloodtx.com
Debt:
  • Current Ratio: 14.05%
  • Quick Ratio: 14.05%
Sales & Book Value:
  • Annual Sales: N/A
  • Price / Sales: N/A
  • Book Value: $5.91 per share
  • Price / Book: 6.49
Profitability:
  • Trailing EPS: ($2.55)
  • Net Income: $-82,460,000.00
  • Return on Equity: -40.04%
  • Return on Assets: -37.24%
Misc:
  • Employees: 95
  • Outstanding Shares: 43,700,000
 

Frequently Asked Questions for Global Blood Therapeutics (NASDAQ:GBT)

What is Global Blood Therapeutics' stock symbol?

Global Blood Therapeutics trades on the NASDAQ under the ticker symbol "GBT."

How were Global Blood Therapeutics' earnings last quarter?

Global Blood Therapeutics, Inc. (NASDAQ:GBT) posted its quarterly earnings results on Thursday, November, 2nd. The company reported ($0.66) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.62) by $0.04. During the same quarter in the previous year, the firm posted ($0.58) earnings per share. View Global Blood Therapeutics' Earnings History.

Where is Global Blood Therapeutics' stock going? Where will Global Blood Therapeutics' stock price be in 2017?

11 Wall Street analysts have issued 12-month price objectives for Global Blood Therapeutics' shares. Their forecasts range from $37.00 to $83.00. On average, they anticipate Global Blood Therapeutics' share price to reach $56.73 in the next twelve months. View Analyst Ratings for Global Blood Therapeutics.

What are Wall Street analysts saying about Global Blood Therapeutics stock?

Here are some recent quotes from research analysts about Global Blood Therapeutics stock:

  • 1. Cowen and Company analysts commented, "GBT reported Q3 earnings last week and provided a brief summary of their progress." (11/9/2017)
  • 2. According to Zacks Investment Research, "Global Blood Therapeutics, Inc. is a biopharmaceutical company which is engaged in discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. Its product candidate consists of GBT440 is an oral, once-daily prophylactic therapy for sickle cell disease which is in clinical trial. The company in addition to GBT is involved in research and development activities targeted hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis and hereditary angioedema. Global Blood Therapeutics, Inc. is based in South San Francisco, California. " (11/7/2017)
  • 3. Wedbush analysts commented, "Global Blood Therapeutics (GBT) is developing GBT440 to reduce the severity and frequency of crises and pain associated with sickle cell disease (SCD) and to improve blood oxygenation characteristics and quality of life for IPF. In 2017, we see release of Phase 2a GBT440 testing in IPF as the most material catalyst unless GBT is acquired. We calculate that the recent uptick following acquisition speculation is too low."We believe GBT440's emerging clinical profile suggests potential for disease modification and becoming the foundation treatment for SCD. To date the emerging clinical profile includes a convenient once daily oral dosing; being safe and well tolerated and recent longer-term dosing suggests durability of effect and in our view partially de-risks Phase 3. Investor concerns include lack of dose response, new PRO and competition." (3/20/2017)
  • 4. Cantor Fitzgerald analysts commented, "We are initiating coverage on Global Blood Therapeutics (GBT) with an Overweight rating and a $61/share price target. We believe Global Blood's lead candidate, GBT440, has demonstrated compelling potential for the treatment of sickle cell disease (SCD), based on its reported clinical efficacy and safety data. Moreover, we believe the mechanism of action of oxygen affinity modulation is strongly validated in the scientific literature. Sickle cell disease remains a therapeutic area with a significant unmet need, for which the only approved therapy demonstrating clinical benefit is carcinogenic. Global Blood is currently enrolling up to 400 patients with SCD in its Phase 3 study." (3/15/2017)
  • 5. J P Morgan Chase & Co analysts commented, "This evening GBT released 4Q results via press release (no conference call, as usual). The update was largely review and in-line with recent commentary; see our takeaways from the J.P. Morgan Healthcare Conference here. More significant than tonight’s print was Reuter’s report last week (here) that Novo Nordisk may have interest in GBT, and a subsequent Reuter’s story (here) that quoted NVO’s CEO saying “In my view we should do smaller deals; low single-digit billions of dollars.” On this front, we do believe that GBT could be a strong strategic fit for companies currently involved in the non-oncology hematology space. More broadly, we continue to think GBT440 is a promising wholly owned asset targeting a large and underserved market with the potential for initial IPF data later this year and a key sickle cell update currently anticipated in 2018." (3/15/2017)

Who are some of Global Blood Therapeutics' key competitors?

Who are Global Blood Therapeutics' key executives?

Global Blood Therapeutics' management team includes the folowing people:

  • Ted W. Love M.D., President, Chief Executive Officer, Director (Age 58)
  • Jeffrey S. Farrow, Chief Financial Officer (Age 55)
  • Peter Radovich, Senior Vice President, Operations (Age 39)
  • Hing L. Sham, Senior Vice President, Research (Age 64)
  • Jung E. Choi, Chief Business and Strategy Officer (Age 47)
  • Tricia Borga Suvari Esq., Chief Legal Officer (Age 56)
  • Charles J. Homcy M.D., Director (Age 68)
  • Willie L. Brown Jr, Independent Director (Age 83)
  • Scott W. Morrison, Independent Director (Age 59)
  • Deval L. Patrick, Independent Director (Age 60)

When did Global Blood Therapeutics IPO?

(GBT) raised $102 million in an initial public offering (IPO) on Wednesday, August 12th 2015. The company issued 6,000,000 shares at $16.00-$18.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Cowen and Company and Wedbush PacGrow were co-managers.

Who owns Global Blood Therapeutics stock?

Global Blood Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Perceptive Advisors LLC (9.76%), Orbimed Advisors LLC (5.48%), Point72 Asset Management L.P. (4.63%), Janus Henderson Group PLC (3.24%), Sectoral Asset Management Inc (1.22%) and Fernwood Investment Management LLC (0.96%). Company insiders that own Global Blood Therapeutics stock include Charles J Homcy, Deval L Patrick, Eleanor Ramos, John Schembri, Jung Choi, Kevin P Starr, Peter Radovich and Robert I Tepper. View Institutional Ownership Trends for Global Blood Therapeutics.

Who sold Global Blood Therapeutics stock? Who is selling Global Blood Therapeutics stock?

Global Blood Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Iguana Healthcare Management LLC, OxFORD Asset Management LLP, Wells Fargo & Company MN, Marcus Capital LLC, Sphera Funds Management LTD., EAM Investors LLC, California State Teachers Retirement System and Cubist Systematic Strategies LLC. Company insiders that have sold Global Blood Therapeutics company stock in the last year include Charles J Homcy, Deval L Patrick, Jung Choi, Kevin P Starr, Peter Radovich and Robert I Tepper. View Insider Buying and Selling for Global Blood Therapeutics.

Who bought Global Blood Therapeutics stock? Who is buying Global Blood Therapeutics stock?

Global Blood Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Janus Henderson Group PLC, Perceptive Advisors LLC, NF Trinity Capital Hong Kong Ltd, Orbimed Advisors LLC, Fernwood Investment Management LLC, Sectoral Asset Management Inc and Cornerstone Capital Management Holdings LLC.. Company insiders that have bought Global Blood Therapeutics stock in the last two years include Eleanor Ramos and John Schembri. View Insider Buying and Selling for Global Blood Therapeutics.

How do I buy Global Blood Therapeutics stock?

Shares of Global Blood Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Global Blood Therapeutics' stock price today?

One share of Global Blood Therapeutics stock can currently be purchased for approximately $38.35.

How big of a company is Global Blood Therapeutics?

Global Blood Therapeutics has a market capitalization of $1.68 billion. The company earns $-82,460,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Global Blood Therapeutics employs 95 workers across the globe.

How can I contact Global Blood Therapeutics?

Global Blood Therapeutics' mailing address is 400 E Jamie Ct Ste 101, SOUTH SAN FRANCISCO, CA 94080-6230, United States. The company can be reached via phone at +1-650-7417700 or via email at [email protected]


MarketBeat Community Rating for Global Blood Therapeutics (GBT)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  210 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  311
MarketBeat's community ratings are surveys of what our community members think about Global Blood Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Global Blood Therapeutics (NASDAQ:GBT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 11 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $56.73 (47.92% upside)

Consensus Price Target History for Global Blood Therapeutics (NASDAQ:GBT)

Price Target History for Global Blood Therapeutics (NASDAQ:GBT)

Analysts' Ratings History for Global Blood Therapeutics (NASDAQ:GBT)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/13/2017Oppenheimer Holdings, Inc.Set Price TargetBuy$53.00N/AView Rating Details
11/9/2017Cowen and CompanyReiterated RatingBuy$83.00N/AView Rating Details
11/6/2017SunTrust Banks, Inc.Boost Price TargetBuy$67.00N/AView Rating Details
10/23/2017J P Morgan Chase & CoReiterated RatingBuyN/AView Rating Details
10/24/2017Needham & Company LLCSet Price TargetBuy$51.00N/AView Rating Details
10/6/2017Morgan StanleyReiterated RatingOverweight$51.00 -> $56.00N/AView Rating Details
9/18/2017WedbushReiterated RatingOurperform$73.00MediumView Rating Details
5/1/2017Janney Montgomery ScottInitiated CoverageBuy$37.00LowView Rating Details
3/20/2017Roth CapitalSet Price TargetBuy$47.00LowView Rating Details
3/15/2017Cantor FitzgeraldInitiated CoverageOverweight -> Overweight$61.00LowView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$50.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
9/30/2016Wells Fargo & CompanyInitiated CoverageOutperform$75.00 -> $23.05N/AView Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$43.00 -> $26.00N/AView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Global Blood Therapeutics (NASDAQ:GBT)

Earnings by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Earnings History by Quarter for Global Blood Therapeutics (NASDAQ GBT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2017Q3 2017($0.62)($0.66)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.61)($0.55)ViewN/AView Earnings Details
5/1/2017Q1 2017($0.71)($0.60)ViewN/AView Earnings Details
3/13/2017Q4 2016($0.64)($0.74)ViewN/AView Earnings Details
11/9/2016Q316($0.58)($0.58)ViewN/AView Earnings Details
8/10/2016Q216($0.63)($0.58)ViewN/AView Earnings Details
5/12/2016Q1($0.48)($0.56)ViewN/AView Earnings Details
3/29/2016Q4($0.64)($0.53)ViewN/AView Earnings Details
11/12/2015Q3 2015($0.71)($0.90)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Global Blood Therapeutics (NASDAQ:GBT)
Current Year EPS Consensus Estimate: $-2.53 EPS
Next Year EPS Consensus Estimate: $-3.06 EPS

Dividends

Dividend History for Global Blood Therapeutics (NASDAQ:GBT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Global Blood Therapeutics (NASDAQ GBT)

Insider Ownership Percentage: 5.30%
Institutional Ownership Percentage: 85.03%
Insider Trades by Quarter for Global Blood Therapeutics (NASDAQ:GBT)
Institutional Ownership by Quarter for Global Blood Therapeutics (NASDAQ:GBT)

Insider Trades by Quarter for Global Blood Therapeutics (NASDAQ GBT)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/30/2017Peter RadovichVPSell12,500$35.00$437,500.00View SEC Filing  
10/27/2017Charles J HomcyDirectorSell70,000$33.97$2,377,900.00View SEC Filing  
10/17/2017Jung ChoiInsiderSell3,000$32.65$97,950.00View SEC Filing  
9/29/2017Jung ChoiInsiderSell3,000$30.00$90,000.00View SEC Filing  
8/31/2017Jung ChoiInsiderSell3,000$30.00$90,000.00View SEC Filing  
7/25/2017Deval L PatrickDirectorSell27,053$29.69$803,203.57View SEC Filing  
7/21/2017Jung ChoiInsiderSell3,000$30.00$90,000.00View SEC Filing  
4/6/2017Robert I TepperMajor ShareholderSell31,225$33.23$1,037,606.75View SEC Filing  
12/16/2016Kevin P StarrMajor ShareholderSell108,955$16.00$1,743,280.00View SEC Filing  
1/7/2016John SchembriinsiderBuy1,500$21.57$32,355.00View SEC Filing  
12/22/2015Eleanor RamosinsiderBuy11,000$20.93$230,230.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Global Blood Therapeutics (NASDAQ GBT)

Source:
DateHeadline
An Integrated Research On Global Blood Therapeutics: Is Voxelotor The Answer For Sickle Cell Disease? - Seeking AlphaAn Integrated Research On Global Blood Therapeutics: Is Voxelotor The Answer For Sickle Cell Disease? - Seeking Alpha
seekingalpha.com - November 19 at 4:15 AM
Global Blood Therapeutics (GBT) versus Oramed Pharmaceuticals (ORMP) Head to Head ContrastGlobal Blood Therapeutics (GBT) versus Oramed Pharmaceuticals (ORMP) Head to Head Contrast
www.americanbankingnews.com - November 16 at 5:20 AM
Global Blood Therapeutics, Inc. (GBT) Given a $53.00 Price Target at Oppenheimer Holdings, Inc.Global Blood Therapeutics, Inc. (GBT) Given a $53.00 Price Target at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - November 13 at 4:31 PM
Global Blood Therapeutics (GBT) Announces Completion of Safety Review by Independent DSMB for Phase 3 HOPE ... - StreetInsider.comGlobal Blood Therapeutics (GBT) Announces Completion of Safety Review by Independent DSMB for Phase 3 HOPE ... - StreetInsider.com
www.streetinsider.com - November 13 at 9:46 AM
Global Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell DiseaseGlobal Blood Therapeutics Announces Completion of Safety Review by Independent Data and Safety Monitoring Board (DSMB) for Phase 3 HOPE Study in Sickle Cell Disease
finance.yahoo.com - November 13 at 9:46 AM
Global Blood Therapeutics, Inc. (GBT) Given Buy Rating at Cowen and CompanyGlobal Blood Therapeutics, Inc. (GBT) Given Buy Rating at Cowen and Company
www.americanbankingnews.com - November 9 at 3:42 PM
January 2018 Options Now Available For Global Blood Therapeutics (GBT) - NasdaqJanuary 2018 Options Now Available For Global Blood Therapeutics (GBT) - Nasdaq
www.nasdaq.com - November 7 at 12:43 AM
Global Blood Therapeutics, Inc. (GBT) Given New $67.00 Price Target at SunTrust Banks, Inc.Global Blood Therapeutics, Inc. (GBT) Given New $67.00 Price Target at SunTrust Banks, Inc.
www.americanbankingnews.com - November 6 at 11:39 AM
Global Blood Therapeutics, Inc. (GBT) Expected to Announce Earnings of -$0.67 Per ShareGlobal Blood Therapeutics, Inc. (GBT) Expected to Announce Earnings of -$0.67 Per Share
www.americanbankingnews.com - November 5 at 11:44 AM
Global Blood Therapeutics, Inc. (GBT) Announces Quarterly  Earnings ResultsGlobal Blood Therapeutics, Inc. (GBT) Announces Quarterly Earnings Results
www.americanbankingnews.com - November 3 at 9:30 PM
Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial ResultsGlobal Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results
www.thestreet.com - November 3 at 12:04 PM
Global Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th ... - GlobeNewswire (press release)Global Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th ... - GlobeNewswire (press release)
globenewswire.com - November 2 at 8:12 PM
Global Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial ResultsGlobal Blood Therapeutics Reports Recent Business Progress and Provides Third Quarter 2017 Financial Results
finance.yahoo.com - November 2 at 8:12 PM
Global Blood reports 3Q lossGlobal Blood reports 3Q loss
finance.yahoo.com - November 2 at 8:12 PM
Global Blood Therapeutics - The Halloween 2017 Bioscience StockGlobal Blood Therapeutics - The Halloween 2017 Bioscience Stock
seekingalpha.com - November 1 at 8:13 PM
Global Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th American Society of Hematology (ASH) Annual MeetingGlobal Blood Therapeutics Announces Upcoming Data Presentations Supporting Sickle Cell Disease Program at 59th American Society of Hematology (ASH) Annual Meeting
finance.yahoo.com - November 1 at 8:13 PM
Global Blood Therapeutics, Inc. (GBT) VP Peter Radovich Sells 12,500 SharesGlobal Blood Therapeutics, Inc. (GBT) VP Peter Radovich Sells 12,500 Shares
www.americanbankingnews.com - October 31 at 11:28 PM
Global Blood Therapeutics, Inc. (GBT) to Release Earnings on TuesdayGlobal Blood Therapeutics, Inc. (GBT) to Release Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:34 AM
Bioscience Catalysts: Global Blood Therapeutics And Vanda PharmaceuticalsBioscience Catalysts: Global Blood Therapeutics And Vanda Pharmaceuticals
seekingalpha.com - October 31 at 5:54 AM
Global Blood Therapeutics: When Single-Patient Data Is A Significant CatalystGlobal Blood Therapeutics: When Single-Patient Data Is A Significant Catalyst
seekingalpha.com - October 30 at 7:51 PM
Global Blood Therapeutics Inc. Jumped as Much as 14% on This NewsGlobal Blood Therapeutics Inc. Jumped as Much as 14% on This News
finance.yahoo.com - October 30 at 7:51 PM
Global Blood Therapeutics Announces Presentation...Global Blood Therapeutics Announces Presentation...
www.benzinga.com - October 30 at 4:07 AM
Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440 ... - GlobeNewswire (press release)Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440 ... - GlobeNewswire (press release)
globenewswire.com - October 29 at 12:22 AM
Global Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440) in a Sickle Cell Disease Patient with Severe and Symptomatic AnemiaGlobal Blood Therapeutics Announces Presentation of Case Study Demonstrating Positive Effect of Voxelotor (GBT440) in a Sickle Cell Disease Patient with Severe and Symptomatic Anemia
finance.yahoo.com - October 28 at 7:21 PM
Charles J. Homcy Sells 70,000 Shares of Global Blood Therapeutics, Inc. (GBT) StockCharles J. Homcy Sells 70,000 Shares of Global Blood Therapeutics, Inc. (GBT) Stock
www.americanbankingnews.com - October 27 at 8:22 PM
Global Blood Therapeutics: Addressing A Sickle That Impedes Critical CyclingGlobal Blood Therapeutics: Addressing A Sickle That Impedes Critical Cycling
seekingalpha.com - October 26 at 8:23 PM
Global Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440 - GlobeNewswire (press release)Global Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440 - GlobeNewswire (press release)
globenewswire.com - October 25 at 6:07 AM
Global Blood To Discontinue GBT 440 Program For Idiopathic Pulmonary FibrosisGlobal Blood To Discontinue GBT 440 Program For Idiopathic Pulmonary Fibrosis
www.rttnews.com - October 25 at 12:46 AM
BRIEF-Global blood Therapeutics reports approval of voxelotor as nonproprietary name for GBT440BRIEF-Global blood Therapeutics reports approval of voxelotor as nonproprietary name for GBT440
www.reuters.com - October 25 at 12:46 AM
Global Blood Therapeutics (GBT) to Discontinue GBT440 Program for Treatment of IPFGlobal Blood Therapeutics (GBT) to Discontinue GBT440 Program for Treatment of IPF
www.streetinsider.com - October 25 at 12:46 AM
Global Blood Therapeutics stock drops 11.5% after discontinuation of pulmonary fibrosis therapyGlobal Blood Therapeutics stock drops 11.5% after discontinuation of pulmonary fibrosis therapy
finance.yahoo.com - October 25 at 12:46 AM
Global Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440Global Blood Therapeutics Announces Approval of First-in-Class “Voxelotor” as Nonproprietary Name for GBT440
finance.yahoo.com - October 25 at 12:46 AM
Needham & Company LLC Reiterates "$51.00" Price Target for Global Blood Therapeutics, Inc. (GBT)Needham & Company LLC Reiterates "$51.00" Price Target for Global Blood Therapeutics, Inc. (GBT)
www.americanbankingnews.com - October 24 at 7:26 PM
Global Blood Therapeutics, Inc. (GBT) Receives Buy Rating from J P Morgan Chase & CoGlobal Blood Therapeutics, Inc. (GBT) Receives Buy Rating from J P Morgan Chase & Co
www.americanbankingnews.com - October 24 at 3:32 PM
Global Blood Therapeutics, Inc. (GBT) PT Set at $53.00 by Oppenheimer Holdings, Inc.Global Blood Therapeutics, Inc. (GBT) PT Set at $53.00 by Oppenheimer Holdings, Inc.
www.americanbankingnews.com - October 23 at 11:58 PM
Pre-Open Movers 10/23: (AIMT) (PETS) (AGEN) Higher; (DBVT) (ATRS) (GBT) Lower (more...) - StreetInsider.comPre-Open Movers 10/23: (AIMT) (PETS) (AGEN) Higher; (DBVT) (ATRS) (GBT) Lower (more...) - StreetInsider.com
www.streetinsider.com - October 23 at 6:41 PM
Global Blood Therapeutics Announces Discontinuation of Idiopathic Pulmonary Fibrosis (IPF) Program - GlobeNewswire (press release)Global Blood Therapeutics Announces Discontinuation of Idiopathic Pulmonary Fibrosis (IPF) Program - GlobeNewswire (press release)
globenewswire.com - October 23 at 6:41 PM
Global Blood Therapeutics stock declines after forsaking half its drug pipelineGlobal Blood Therapeutics stock declines after forsaking half its drug pipeline
finance.yahoo.com - October 23 at 6:41 PM
Jung Choi Sells 3,000 Shares of Global Blood Therapeutics, Inc. (GBT) StockJung Choi Sells 3,000 Shares of Global Blood Therapeutics, Inc. (GBT) Stock
www.americanbankingnews.com - October 18 at 8:10 PM
Global Blood Therapeutics, Inc. (GBT) Lowered to Hold at Zacks Investment ResearchGlobal Blood Therapeutics, Inc. (GBT) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - October 16 at 11:20 PM
Global Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant GenotypeGlobal Blood Therapeutics Announces Presentation of New Data Showing Positive Effect of GBT440 on Sickle Cell Disease Patient with Variant Genotype
finance.yahoo.com - October 12 at 2:13 AM
Global Blood Therapeutics, Inc. (GBT) Given a $53.00 Price Target by Oppenheimer Holdings, Inc. AnalystsGlobal Blood Therapeutics, Inc. (GBT) Given a $53.00 Price Target by Oppenheimer Holdings, Inc. Analysts
www.americanbankingnews.com - October 11 at 4:38 PM
Global Blood Therapeutics, Inc. (GBT) Given Overweight Rating at Morgan StanleyGlobal Blood Therapeutics, Inc. (GBT) Given Overweight Rating at Morgan Stanley
www.americanbankingnews.com - October 7 at 12:22 PM
Critical Analysis: Global Blood Therapeutics (GBT) versus Caladrius Biosciences (CLBS)Critical Analysis: Global Blood Therapeutics (GBT) versus Caladrius Biosciences (CLBS)
www.americanbankingnews.com - October 5 at 8:28 PM
Global Blood Therapeutic Earns Relative Strength Rating UpgradeGlobal Blood Therapeutic Earns Relative Strength Rating Upgrade
finance.yahoo.com - October 5 at 6:16 PM
Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings ... - GlobeNewswire (press release)Global Blood Therapeutics Announces Upcoming Presentations of GBT440 Data at Two Sickle Cell Disease Meetings ... - GlobeNewswire (press release)
globenewswire.com - October 5 at 8:35 AM
Steven Cohen Doubles Down on Sickle Cell Disease Therapeutics Company Global BloodSteven Cohen Doubles Down on Sickle Cell Disease Therapeutics Company Global Blood
finance.yahoo.com - October 5 at 8:35 AM
Global Blood Therapeutics, Inc. (GBT) Given Average Recommendation of "Buy" by AnalystsGlobal Blood Therapeutics, Inc. (GBT) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - October 4 at 6:04 PM
BRIEF-Point72 Asset Management LP reports 5.2 pct passive stake in Global Blood TherapeuticsBRIEF-Point72 Asset Management LP reports 5.2 pct passive stake in Global Blood Therapeutics
www.reuters.com - October 4 at 11:10 AM
After-Hours Stock Movers 10/03: (CTMX) (I) (GBT) Higher; (ODP) (NLNK) (RIGL) Lower (more...)After-Hours Stock Movers 10/03: (CTMX) (I) (GBT) Higher; (ODP) (NLNK) (RIGL) Lower (more...)
www.streetinsider.com - October 4 at 11:10 AM

Social Media

Financials

Chart

Global Blood Therapeutics (NASDAQ GBT) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.